In phase 2 trial, novel therapy significantly reduced triglyceride levels

Coverage, in order

1. 2d ago
   
   Medical Xpress indie study randomized trialpeer-reviewedn=12

   In phase 2 trial, novel therapy significantly reduced triglyceride levels

   A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are published in the New…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.